Autres langues Orthocell Limited

Actions

Marché Fermé - Australian S.E. Autres places de cotation 07:05:57 14/05/2024			Varia. 5j.	Varia. 1 janv.
0,4 ^AUD	+2,56%		+2,56%	-2,44%

04:38	La membrane dentaire Striate+ d'Orthocell obtient un taux de réussite de 98,6 % dans le cadre d'une étude clinique post-commercialisation ; les actions progressent de 3 %.	MT
15/04	Orthocell obtient un rabais fiscal de 3 millions de dollars australiens sur la recherche et le développement pour l'exercice 2023 ; les actions augmentent de 3 %.	MT

Orthocell's Striate+ Dental Membrane Product Achieves 98.6% Success Rate in Post-Market Clinical Study; Shares Up 3%	04:38
Orthocell Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 3%	15/04
Orthocell Revenue Soars 19% to AU$1.61 Million in Q1	09/04
Orthocell Completes First Stage of Remplir US Market Authorization Study	25/03
Orthocell raising $3.5 million; adds heavy hitters to register	23/02
Orthocell Limited Reports Earnings Results for the Half Year Ended December 31, 2023	23/02
Orthocell Completes AU$3.5 Million Share Placement	22/02
Orthocell Submits Regulatory Application for Remplir in Singapore	13/02
Orthocell Limited Announces Resignation of Matthew Callahan from the Board	15/01
Orthocell Limited Appoints Kim Beazley AC as an Independent Non-Executive Director	14/01
Orthocell Completes Chair Transition Process	22/12
Orthocell Limited Announces Changes to its Board	21/12
Orthocell on the cusp of significant growth	01/11
Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023	24/10/23
Orthocell Limited Announces Board Changes	24/10/23
Orthocell Limited Announces Board Changes	22/09/23
Orthocell Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23
Orthocell Secures Over AU$3 Million R&D Tax Rebate	21/06/23
Orthocell thrilled to welcome John Van Der Wielen as chairman	29/05/23
Orthocell Appoints Nonexecutive Chair	29/05/23

Aucun résultat pour cette recherche